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Purpose of the study: The molecular mechanism of lymphovascular invasion (LVI) 
which determines the early metastatic phenotype in breast cancer is still not fully 
understood. Lead from the METABRIC study revealed that MED23 correlated with 
negative LVI status (p=0.00005). Hence MED23 expression was studied at the protein 
level for correlations with LVI and other clinical-pathological parameters. 
Methods: The METABRIC BC cohort (n=1980) was evaluated for MED23 mRNA 
expression and prognostic impact externally validated using the online bc-GenExminer 
4.0. Correlation between MED23 protein expression with clinico-pathological 
parameters, patient outcome and other biomarkers were explored (Nottingham 
Tenovus series; n=1255) using immunohistochemistry (IHC). 
Results: High MED23 mRNA expression was negatively associated with tumour 
stage and was differentially expressed in good prognosis integrative clusters 7 and 8 
(p<0.001). MED23 IHC revealed nuclear expression (n-MED23). Although no association 
was found with LVI, higher n-MED23 expression correlated with low NPI, low grade, 
older age, ER+ status, low Ki67 index and low N-cadherin expression (p<0.05). Positive 
correlations with PTEN, GATA3, STAT3 and CDC42 (p<0.001), indicate possible 
interacting pathways. In univariate analysis, high n-MED23 expression showed better 
long-term patient outcome in the whole cohort and ER+ subgroups (p<0.05). Pooled 
MED23 expression in an external validation cohort (ER+LN-) also showed association 
with better patient outcome (p<0.02, HR=0.82, 95% CI 0.69-0.98). 
Conclusion: Results of the study suggest that loss of n-MED23 is a marker of poor 
prognosis in invasive BC, results re-enforced by expression data. The difference 
in correlation with LVI at gene and protein level highlights the importance of IHC 
validation and indicates MED23 as a probable bystander in the LVI cascade. 
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